{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:17Z","timestamp":1793094377142,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>\n              This phase II trial (ClinicalTrials.gov identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04617756\">NCT04617756<\/jats:ext-link>\n              ) included patients with nonmetastatic, high-grade UTUC, on the basis of the ureteroscopic biopsy or urine cytology, and\/or infiltrative aspect of the renal pelvis\/ureteral wall by computed tomography imaging. Before RNU, patients received durvalumab plus gemcitabine\/cisplatin (cohort 1) or durvalumab plus gemcitabine\/carboplatin (cohort 2) once every 3 weeks for a total of four cycles (cohort choice on the basis of the glomerular filtration rate). The primary objective was the pathologic complete response (ypT0) rate in each cohort.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Fifty patients were enrolled between 2021 and 2024 (31 in cohort 1; 19 in cohort 2). Median age was 68 years (range, 38-79), and 59% were men. Forty-five patients received four cycles of treatment, three patients three cycles, and one patient two cycles. Five patients switched to carboplatin during treatment. At surgery (N = 45 patients), rates of pT0 were 13% (4\/29) in cohort 1 and 5% (1\/19) in cohort 2. Fifty percent (15\/29) of patients were pTa\/pT1 in cohort 1, and 42% (8\/19) in cohort 2. No severe immunotherapy-mediated toxicity was observed. Four patients had chemotherapy-related grade 3 neutropenia, one grade 4; one patient had grade 3 thrombopenia, one grade 4; and four patients had grade 3 anemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-25-00179","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:20:12Z","timestamp":1739550012000},"page":"1578-1586","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":23,"title":["Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine\/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04617756","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-5754","authenticated-orcid":true,"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"first","affiliation":[{"name":"Department of Oncology, CHU Ni\u0302mes, Ni\u0302mes, France"},{"name":"INSERM U1194, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chevallier","sequence":"additional","affiliation":[{"name":"CHU N\u00eemes, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, N\u00eemes, France"},{"name":"UMR 1302, Desbrest Institute of Epidemiology and Public Health, INSERM, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-2075","authenticated-orcid":true,"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[{"name":"Department of Urology, Georges Pompidou European Hospital, AP-HP Centre, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":true,"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Georges Pompidou European Hospital, AP-HP, Paris Cit\u00e9 University, Paris, France"},{"name":"Institut Du Cancer Paris CARPEM, AP-HP Centre, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[{"name":"Department of Urology, Foch Hospital, Paris-Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Oncology, Foch Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-3236","authenticated-orcid":true,"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, U976 HIPI, Saint-Louis Research Institute, Paris, France"},{"name":"Urology Department, APHP, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1554","authenticated-orcid":true,"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Paoli-Calmettes Institute, Aix Marseille University, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Paoli-Calmettes Institute, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tartas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Canc\u00e9rologie des Hospices de Lyon (IC-HCL), Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[{"name":"Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon Sud Medical School, University of Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Oncopole Claudius Regaud - IUCT-O, Toulouse, France"},{"name":"Toulouse Cancer Research Centre, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-146X","authenticated-orcid":true,"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[{"name":"Department of Urology, CHU Toulouse, Toulouse III University, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Eugene Marquis Cancer Center, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[{"name":"Department of Urology, Rennes University, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[{"name":"Department of Urology, Bichat Claude-Bernard Hospital, AP-HP Nord, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Jaffrelot","sequence":"additional","affiliation":[{"name":"Department of Oncology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-6964","authenticated-orcid":true,"given":"St\u00e9phane","family":"Droupy","sequence":"additional","affiliation":[{"name":"Department of Urology, CHU Ni\u0302mes, Montpellier University, Ni\u0302mes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Luquiens","sequence":"additional","affiliation":[{"name":"CHU N\u00eemes, Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[{"name":"Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.030"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.013"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30415-3"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01659"},{"key":"e_1_3_10_6_2","article-title":"The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN)","author":"Carpinito GP","unstructured":"Carpinito GP, Gerald T, Hensley PJ, et al: The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN). Urol Oncol 10.1016\/j.urolonc.2024.11.025 [epub ahead of print on December 24, 2024]","journal-title":"Urol Oncol"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102224"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15230"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000644"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00763"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2024.23214"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.039"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2039"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04596-5"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02875-8"},{"key":"e_1_3_10_17_2","volume-title":"TNM Classification of Malignant Tumours, 8th ed","author":"Brierley JD","year":"2016","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumours, 8th ed., Chichester, UK: Wiley-Blackwell, 2016"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28655"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1995-z"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.12.054"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06766.x"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102722"},{"key":"e_1_3_10_24_2","unstructured":"Prost D Pachev A De Kerviler E et al: Oncological safety and diagnostic yield of percutaneous needlecore biopsies in upper tract urothelial carcinoma: The upercut. Eur Urol Oncol (in press)"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16129"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.024"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T21:59:21Z","timestamp":1745877561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1200\/JCO-25-00179"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00179","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}